MeSH D003327 - coronary disease
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D017202:Myocardial ischemia
0 Companies
0 Drugs
Success rate
D003327:Â
Coronary disease
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Eptifibatide | Eptifibatide |  | 2015-06-12 |  |  |
| Isosorbide | Isosorbide |  | 2000-06-19 |  |  | |
| Mylan | Eptifibatide | Eptifibatide |  | 2018-07-20 |  |  |
| GSK | Eptifibatide | Integrilin |  | 1999-07-01 |  |  |
| Sandoz | Isosorbide | Isosorbide |  | 1988-01-07 |  |  |
| AstraZeneca | Isosorbide | Sorbitrate |  | 1990-08-21 |  |  |
| Wyeth | Isosorbide | Isordil |  | 1988-07-29 |  |  |
| Bausch Health Companies | Isosorbide | Isordil |  | 1988-07-29 |  |  |
| Merck & Co | Isosorbide | Imdur |  | 1993-08-12 |  |  |
| Eptifibatide | Integrilin |  | 1998-05-18 |  |  | |
| Vorapaxar | Zontivity |  | 2015-01-19 |  |  | |
| Aurobindo Pharma | Isosorbide | Isosorbide |  | 2022-11-07 |  |  |
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
38%3/8
Phase 2
63%33/52
Phase 3
32%28/87
Approved: 5Overall Success rate: 8%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use